Application notes:
Biosensors
Sophomer F10 surpasses BSA in exosome biosensor immobilization, significantly reducing non-specific binding and enhancing sensitivity. As demonstrated by fluorescence assays, the detailed protocol yields high capture efficiency even at low exosome concentrations. This polymer’s superior performance stems from its flexibility and consistent surface passivation, making it ideal for precise exosome-based diagnostics.
ELISA
This study directly compares the blocking efficacy of SophoMer F10 and BSA in two ELISA-based assays. Results demonstrate that SophoMer F10 significantly outperforms BSA in reducing non-specific binding, achieving comparable signal reduction at five times lower concentrations. This superior performance, confirmed across two distinct experimental protocols (one using HRP alone, the other an HRP-antibody conjugate), is evidenced by significantly lower coefficients of variation, indicating greater assay consistency.
Immunoblotting
This research validates the use of SophoMer F10 as a replacement for BSA in ELISA and immunoblotting, showcasing its effectiveness in characterizing the novel GCP3-01 monoclonal antibody. The study demonstrates GCP3-01’s high specificity for the GCP3 protein, precisely mapping its epitope within the N-terminal domain (amino acids 14-23). The successful application of SophoMer F10 highlights its utility in improving the sensitivity and reliability of antibody characterization assays, which is particularly valuable given the known dysregulation of GCP3 in cancer.
Research papers:
Highly Effective Synthetic Polymer-Based Blockers of Non-Specific Interactions in Immunochemical Analyses
This research introduces a novel, highly effective synthetic polymer-based blockers for non-specific binding in immunochemical assays, offering a superior alternative to BSA. The study details the synthesis and characterization of amphiphilic HPMA and poly(oxazoline) copolymers, demonstrating their superior performance in reducing non-specific binding compared to BSA across multiple ELISA assays, including a clinically relevant TSH assay.